Elekta AB (publ) EKTA-B.ST
Nasdaq Stockholm · Healthcare · Medical Devices
60.75 SEK
−0.7%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Elekta
| SEK million | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 16,869 | 18,119 | 18,016 | 16,718 |
| EBITDA | 2,570 | 3,163 | 2,206 | 1,412 |
| Net income | 943 | 1,302 | 237 | −519 |
| Balance sheet | ||||
| Equity | 9,729 | 10,775 | 8,802 | 7,098 |
| Total debt | 6,668 | 7,248 | 7,567 | 7,331 |
| Cash | 3,270 | 2,771 | 2,947 | 3,167 |
| Net debt | 3,398 | 4,477 | 4,620 | 4,164 |
| Ratios and per share | ||||
| EBITDA margin | 15.2% | 17.5% | 12.2% | 8.4% |
| Profit margin | 5.6% | 7.2% | 1.3% | −3.1% |
| Return on equity | 9.7% | 12.1% | 2.7% | −7.3% |
| Earnings/share (SEK) | 2.47 | 3.41 | 0.62 | −1.36 |
| Book value/share (SEK) | 25.46 | 28.20 | 23.04 | 18.58 |
| Shares outstanding (M) | 382 | 382 | 382 | 382 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | – |
| P/B | 3.3 |
| EV / EBITDA | 19.4 |
| Net debt / EBITDA | 2.9 |
| Return on equity | −7.3% |
| Profit margin | −3.1% |
| Beta 1Y | 0.92 |
| Revenue growth 1Y | −7.2% |
| Revenue CAGR 3Y | −0.3% |
| ROE avg. 3Y | 2.5% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (SEK)
| 2026 | 2.40 |
| 2025 | 2.40 |
| 2024 | 2.40 |
| 2023 | 2.40 |
| 2022 | 2.30 |
Not investment advice. Figures may contain errors from the data source.